| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:NNC 711;1,2,5,6-Tetrahydro-1-[2-[[(diphenylMethylene)aMino]oxy]ethyl]-3-pyridinecarboxylicacidhydrochloride
CAS:145645-62-1
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:NO-711
CAS:145645-62-1
Purity:>=98% (HPLC) Package:5mg, 25mg Remarks:N142
|
1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE manufacturers
- NNC 05-711
-
- $42.00 / 1mg
-
2025-11-09
- CAS:145645-62-1
- Min. Order:
- Purity: 99.92%
- Supply Ability: 10g
|
| | 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Basic information |
| Product Name: | 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE | | Synonyms: | NO-711 HYDROCHLORIDE;NNC 711;1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE;1-(2-(((DIPHENYLMETHYLENE)IMINO)OXY)ETHYL)-1,2,5,6-TETRAHYDRO-3-PYRIDINE CARBOXYLIC ACID HYDROCHLORIDE;NO-711 HCL POTENT GABA UPTAKE IN;1,2,5,6-Tetrahydro-1-(2-(((diphenylmethylene)amino)oxy]ethyl)-3-pyridinecarboxylicacidhydrochloride;NNC711,HCl;1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride | | CAS: | 145645-62-1 | | MF: | C21H23ClN2O3 | | MW: | 386.87 | | EINECS: | | | Product Categories: | GABA/Glycine receptor | | Mol File: | 145645-62-1.mol | ![1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Structure](CAS/GIF/145645-62-1.gif) |
| | 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Chemical Properties |
| storage temp. | protect from light | | solubility | H2O: ≥10 mg/mL at 60 °C | | form | solid | | color | off-white | | Water Solubility | H2O: 10mg/mL at60°C |
| | 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Usage And Synthesis |
| Uses | NNC 711 is an anticonvulsant agent and a selective GABA uptake inhibitor (1,2). | | Uses | NO-711 hydrochloride is suitable for use as γ-aminobutyric acid (GABA) transporter-1 (GAT-1) antagonists or GABA uptake inhibitor. | | Biological Activity | Potent and selective inhibitor of GABA uptake by GAT-1 (IC 50 values are 0.04, 171, 1700 and 622 μ M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo . | | Biochem/physiol Actions | NO-711 is a potent and selective GABA uptake inhibitor that crosses the blood-brain barrier. | | in vivo | NNC-711 (0.25-3 mg/kg; i.p.; 30 min prior to training) prevents amnesia for a passive avoidance task induced by the acetylcholine receptor antagonist Scopolamine (HY-N0296) in male Wistar rat[2].
NNC-711 (0.5-3 mg/kg; i.p.; immediately prior to occlusion) protects against ischemia-induced death of CA1 pyramidal neurons in a model of bilateral common carotid artery occlusion in the gerbil[2].
NNC-711 (0.5-1.5 mg/kg; i.p.; immediately prior to training) exhibits significant cognition-enhancing actions in postnatal day 80 male and 28-month old female Wistar rats[2].
NNC-711 (NO-711) (50-200 μg/10 μL; i.t.; once) effectively develops analgesic effect in sciatic nerve CCI rats modelc[3].
NNC-711 (0.3-30 mg/kg, i.p.; 30 min before testing) exhibits anticonvulsant effects in Multiple mices and rats epilepsy model[4].
| Animal Model: | DMCM (HY-100369A)-induced seizures in female NMRI mice (20 g), pentylenetetrazole-induced seizures in male NMRI mice and male albino Wistar SPF rats (150-200 g), Audiogenic seizures in male DBA/2 mice (8 g) [4] | | Dosage: | 0.3-30 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 30 min prior to the seizure test | | Result: | Inhibited DMCM-induced clonic seizures in NMRI mice with an ED50 = 1.2 mg/kg. |
| Animal Model: | Postnatal day 80 male Wistar rats (300-350 g)[2] | | Dosage: | 0.25, 0.5, 1, 3 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 30 min prior to training | | Result: | Significantly reversed the amnesia induced by scopolamine administration 6-h post-training when retrieval was tested at 24-h post-training.
Had no effect on learning in the 0.25-0.5 mg/kg dose range, and induced amnesia at 3.0 mg/kg.
Not to directly interact with the cholinergic system, but rather to have a more general neuroprotective action on the consolidation process.
|
| Animal Model: | Postnatal day 80 male Mongolian gerbils (50-65 g)[2] | | Dosage: | 0.5, 3 mg/kg | | Administration: | Intraperitoneal injection (i.p.); immediately prior to occlusion | | Result: | Administrated immediately prior to occlusion significantly reduced CA1 cell death. |
| Animal Model: | Postnatal day 80 male Wistar rats (300-350 g) and 28-month old female Wistar rats[2] | | Dosage: | 0.5, 1.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.); immediately prior to training | | Result: | Significantly reduced escape latencies in both mature postnatal day 80 and aged 28 months rats.
Improved rats ability to locate the hidden platform at 0.5 mg/kg, but the effect was reduced at 1.5 mg/kg.
Had no effect on memory retention.
|
| Animal Model: | Sciatic nerve chronic constriction injury (CCI) rats[3] | | Dosage: | 50, 100, 200 μg/10 μL | | Administration: | Intrathecal (i.t.); once | | Result: | Increased withdrawal thresholds (WT) and withdrawal latency (WL) values after 1 day compared with CCI + saline group.
The maximum value of WT was achieved 3 days after administration and maximum value of WL was achieved 1 day after administration.
|
| | storage | Desiccate at +4°C |
| | 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Preparation Products And Raw materials |
|